Feedback
Settings

Settings

Goto Application

985,665 results
Offices all Languages en Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12N15/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 98,567
1.WO/2026/000762MICROFLUIDIC CHIP AND INFLUENZA A VIRUS DETECTION KIT
WO - 02.01.2026
Int.Class B01L 3/00
BPERFORMING OPERATIONS; TRANSPORTING
01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
3Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
 Appl.No PCT/CN2024/130123 Applicant SHENZHEN YHLO BIOTECH CO., LTD. Inventor WANG, Yuning
The present application belongs to the field of in vitro diagnostics, and particularly relates to a microfluidic chip and an influenza A virus detection kit. The chip comprises a cover plate, a first holding plate, a second holding plate and a bottom plate arranged in sequence from top to bottom, wherein the cover plate is provided with a first sample-loading cavity; the first holding plate is provided with a second sample-loading cavity, a first buffer cavity and a test paper cavity that are connected in sequence by means of a flow channel; and the second holding plate is provided with a reaction cavity, a second buffer cavity and a water absorption cavity that are connected in sequence by means of a flow channel. The microfluidic chip is ingeniously configured as an integrated small detection device. The structure of the microfluidic chip is located on different chip layers, thereby ensuring the independent operation of each operation unit. The aligned buffer cavities are provided between two interlayers, and the design of the buffer cavities enables a product to be fully and uniformly diluted; a sliding device can precisely control the release of a dilution; and the water absorption cavity can absorb the redundant dilution, thereby ensuring that a chromatography test strip can clearly and accurately display the result. By means of the device, the effects of simplifying test steps and preventing contamination can be achieved.
2.WO/2026/000927CENTRIFUGAL MICROFLUIDIC PLATFORM AND NUCLEIC ACID EXTRACTION AND AMPLIFICATION METHOD THEREFOR
WO - 02.01.2026
Int.Class C12M 1/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY
1Apparatus for enzymology or microbiology
 Appl.No PCT/CN2024/143860 Applicant ZHEJIANG PUSHKANG BIOTECHNOLOGY CO., LTD. Inventor YU, Bo
A centrifugal microfluidic platform and a nucleic acid extraction and amplification method therefor. The centrifugal microfluidic platform comprises a disk body and at least one microfluidic structure. Each of the at least one microfluidic structure comprises a sample storage tank, a first reaction tank, a non-polar solution storage tank, a non-polar solution accommodation tank, an elution tank, a polar solution storage tank, and a back-end reaction module. The first reaction tank is connected to the sample storage tank, and the non-polar solution storage tank is connected to the first reaction tank. A first end of the non-polar solution accommodation tank is connected to the first reaction tank by means of a bridge, and a first end of the elution tank is connected to a second end of the non-polar solution accommodation tank by means of a bridge. The polar solution storage tank is connected to the elution tank, and the back-end reaction module is connected to the elution tank.
3.WO/2026/001002DUAL-TARGET MIRNA DETECTION METHOD BASED ON CRISPR AND ROLLING CIRCLE AMPLIFICATION
WO - 02.01.2026
Int.Class C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
 Appl.No PCT/CN2025/076820 Applicant HAINAN YILING MEDICAL INDUSTRY & DEVELOPMENT CO.LTD Inventor SU, Xueming
A dual-target miRNA detection method based on CRISPR and rolling circle amplification, comprising the following steps: (1) mixing a padlock probe, a ligation DNA, miRNA-21, and miRNA-155, performing annealing, incubating with a DNA ligase in a ligase reaction buffer system, and then terminating the reaction by means of heat treatment to obtain a circular DNA template; (2) incubating the circular DNA template with a DNA polymerase, dNTPs, recombinant albumin, a primer, and a polymerase reaction buffer, and then terminating the reaction by means of heat treatment to obtain an RCA product; (3) adding pre-assembled Cas12a-crRNA, the RCA product, and an FQ fluorescent probe to a buffer, and incubating; and (4) measuring fluorescence signals. By means of optimizing the detection system, the detection of dual-target miRNAs is successfully achieved, and the detection sensitivity is high.
4.WO/2026/004992METHOD FOR PRODUCING OSTEOBLAST-CONTAINING CELL MASS
WO - 02.01.2026
Int.Class C12N 5/077
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
077Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
 Appl.No PCT/JP2025/023132 Applicant CELLAXIA INC. Inventor SEKI, Makoto
The purpose of the present invention is to three-dimensionally culture osteoblasts produced with a direct conversion technique, and to provide a three-dimensional bone-like tissue composed of the osteoblasts and bone matrix. The present invention relates to, for example, a method for producing an osteoblast-containing three-dimensional cell mass, comprising: a first step for performing direct conversion from somatic cells of mammals into osteoblasts; a second step for subjecting cells having undergone the first step to high-density culture, and forming a cell sheet containing the osteoblasts; and a third step for obtaining an osteoblast-containing three-dimensional cell mass from the cell sheet obtained in the second step.
5.WO/2026/002052BINDING MOLECULE TARGETING CD3 AND HER2
WO - 02.01.2026
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No PCT/CN2025/103500 Applicant MIANYILI BIOTECH (SHANGHAI) CO., LTD. Inventor HUANG, Zhiwei
Provided is a bispecific antibody targeting a CD3 molecule and a tumor associated antigen (TAA) HER2, comprising a first binding domain targeting the CD3 molecule and a second binding domain targeting HER2, wherein the first binding 5-domain only binds to an epsilon(ε) subunit in a delta(δ)-epsilon(ε) heterodimer of the CD3 molecule, and does not bind to an epsilon(ε) subunit in a gamma(γ)-epsilon(ε) heterodimer of the CD3 molecule. The antibody has the activity of activating immune cells and triggering relatively less cytokine release, recruits T cells, and achieves a cell killing effect.
6.WO/2026/002277TAU-TARGETING RNA INTERFERENCE METHOD, NUCLEIC ACID AND APPLICATION THEREOF
WO - 02.01.2026
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/CN2025/105696 Applicant EXORNA BIOSCIENCE (NANJING) CO., LTD. Inventor GUO, Peipei
The present invention provides a nucleic acid molecule used for regulating the level or amount of Tau mRNA. Specifically, the present invention provides the delivery of a primary microRNA to form a precursor after in vivo processing, and a microRNA used for the in vivo inhibition of the expression of Tau mRNA. The present invention also provides a delivery system for the nucleic acid molecule, comprising a vector, an exosome and a cell, and a pharmaceutical composition containing same. The present invention also provides an application of the nucleic acid molecule and the delivery system in neurodegenerative disease treatment and drug preparation, in particular a method and a drug targeting Alzheimer's disease.
7.WO/2026/003522A METHOD OF CAPTURING NUCLEIC ACIDS
WO - 02.01.2026
Int.Class C08F 220/06
CCHEMISTRY; METALLURGY
08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
FMACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
220Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide, or nitrile thereof
02Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
04Acids; Metals salts or ammonium salts thereof
06Acrylic acid; Methacrylic acid; Metal salts or ammonium salts thereof
 Appl.No PCT/GB2025/051410 Applicant BIOCAPTIVA LIMITED Inventor OWENS, Matthew John Simmonte
The present invention relates to a method of capturing nucleic acids from an aqueous sample, including providing an apparatus configured to capture the nucleic acids from the aqueous sample, wherein the apparatus comprises a substrate which is a copolymer or is provided with said copolymer, the copolymer comprising nucleobase- containing moieties, positively charged moieties at pH from 2 to 11 adapted to bind the nucleic acids via electrostatic interaction, and uncharged moieties, and wherein the aqueous sample is selected from environmental water samples, industrial water samples, wastewater samples, and excretory fluid samples. The method further includes contacting the aqueous sample comprising the nucleic acids with the nucleobase-containing copolymer, and allowing the nucleic acids to bind to the nucleobase-containing copolymer thereby capturing said nucleic acids by said copolymer. The present invention also relates to the copolymer and the apparatus.
8.WO/2026/004362METHOD FOR PRODUCING MAMMALIAN CELLS LABELED BY CHROMOPROTEIN, AND METHOD FOR SCREENING CHROMOPROTEIN
WO - 02.01.2026
Int.Class C12N 5/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
 Appl.No PCT/JP2025/017189 Applicant HAMAMATSU PHOTONICS K.K. Inventor TAKEUCHI Kozo
Provided are: a method for producing mammalian cells labeled by a chromoprotein that includes culturing, at less than 37° C, mammalian cells into which a nucleic acid that expresses a chromoprotein has been introduced; and a method for screening a chromoprotein that includes culturing, at less than 37° C, mammalian cells into which a nucleic acid that expresses a candidate protein has been introduced and evaluating the visible light absorption of the mammalian cells.
9.WO/2026/005622GALLID ALPHAHERPESVIRUS 3 (MDV-2), A VIRAL VECTOR AGAINST DIFFERENT AVIAN PATHOGENS: A NEW VACCINATION STRATEGY IN THE POULTRY FARMING INDUSTRY
WO - 02.01.2026
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
 Appl.No PCT/PE2025/050008 Applicant FARMACOLOGICOS VETERINARIOS S.A.C Inventor FERNANDEZ DIAZ, Manolo Clemente
The present invention relates to the veterinary field in general and specifically to the development of vectored vaccines using the Gallid alphaherpesvirus 3 (GaHV-3) or Marek's disease serotype 2 (MDV-2) vector, which contains protective antigens against different avian pathogens such as Newcastle disease virus (NDV), infectious laryngotracheitis virus (ILTV), infectious bursal disease virus (IBDV) or Gumboro disease, avian influenza virus (AIV), and infectious bronchitis virus (IBV).
10.WO/2026/006147GPC3 BINDING DOMAIN COMPRISING CHIMERIC ANTIGEN RECEPTORS
WO - 02.01.2026
Int.Class A61K 40/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
40Cellular immunotherapy
10characterised by the cell type used
17Monocytes; Macrophages
 Appl.No PCT/US2025/034732 Applicant MODERNATX, INC. Inventor CONDAMINE, Thomas Claude Henri
Provided are GPC3 binding CAR polypeptides, nucleic acids (e.g., mRNA) encoding same, and delivery vehicles (e.g., LNPs) formulated with the nucleic acids. These GPC3 binding CARs can be used to treat any disease with abnormal GPC3 expression, e.g., GPC3+ cancers or tumors, in a subject (e.g., human) in need thereof.
# -